z-logo
Premium
Melatonin‐mediated Bim up‐regulation and cyclooxygenase‐2 ( COX ‐2) down‐regulation enhances tunicamycin‐induced apoptosis in MDA ‐ MB ‐231 cells
Author(s) -
Woo Seon Min,
Min Kyoungjin,
Kwon Taeg Kyu
Publication year - 2015
Publication title -
journal of pineal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 131
eISSN - 1600-079X
pISSN - 0742-3098
DOI - 10.1111/jpi.12217
Subject(s) - melatonin , tunicamycin , apoptosis , cyclooxygenase , microbiology and biotechnology , biology , chemistry , medicine , pharmacology , endocrinology , enzyme , biochemistry , unfolded protein response
Melatonin is involved in many physiological functions, and it has differential effects on apoptosis in normal and cancer cells. However, the mechanism of its antitumor roles is not well understood. In this study, we show that melatonin enhances tunicamycin‐induced apoptosis in human breast carcinoma MDA‐MB‐231 cells. Melatonin up‐regulates pro‐apoptotic protein Bim expression at the transcriptional levels in the presence of tunicamycin. Melatonin inhibits tunicamycin‐induced COX‐2 expression in MDA‐MB‐231 cells. Furthermore, inhibition of COX‐2 activity using the COX‐2 inhibitor, NS398, increases tunicamycin‐induced apoptosis. Interestingly, these effects were not associated with melatonin receptor signal pathways. Pertussis toxin (a general G i protein inhibitor) or luzindole (a nonspecific melatonin receptor antagonist) did not reverse the effect of melatonin. In addition, melatonin blocked tunicamycin‐induced NF‐κB transcriptional activity, p65 nuclear translocation, and p38 MAPK activation. Melatonin‐mediated p38 MAPK inhibition contributed to decreased COX‐2 mRNA stability. Taken together, our results suggest that melatonin enhances antitumor function through up‐regulation of Bim expression and down‐regulation of COX‐2 expression in tunicamycin‐treated MDA‐MB‐231 cells.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here